Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GJB2 | P29033 | 2/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | LGALS8 | O00214 | 5/20 | 0.35 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.35 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.35 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.33 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.33 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16254154 | 0.95 | TNF (0.47) | TNFMAPK1GJB2GBA1LGALS8 | |
| SCHEMBL27099540 | 0.95 | TNF (0.47) | TNFMAPK1GJB2GBA1LGALS8 | |
| SCHEMBL11066796 | 0.94 | TNF (0.50) | TNFMAPK1GJB2GBA1LGALS8 | |
| SCHEMBL10776044 | 0.94 | TNF (0.50) | TNFMAPK1GJB2GBA1LGALS8 | |
| SCHEMBL15003220 | 0.94 | TNF (0.46) | TNFMAPK1GJB2GBA1LGALS8 | |
| SCHEMBL463607 | 0.94 | TNF (0.46) | TNFMAPK1GJB2GBA1LGALS8 | |
| SCHEMBL12898607 | 0.94 | TNF (0.46) | TNFMAPK1GJB2GBA1LGALS8 | |
| SCHEMBL15003149 | 0.94 | TNF (0.46) | TNFMAPK1GJB2GBA1LGALS8 | |
| SCHEMBL15304386 | 0.94 | TNF (0.46) | TNFMAPK1GJB2GBA1LGALS8 | |
| SCHEMBL9008143 | 0.94 | TNF (0.46) | TNFMAPK1GJB2GBA1LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9163047-B2 | Saccharide structures and methods of making and using such structures | MOMENTA PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140200339-A1 | SACCHARIDE STRUCTURES AND METHODS OF MAKING AND USING SUCH STRUCTURES | MOMENTA PHARMACEUTICALS, INC. (US) | 2014-07-17 | — | — | US | disclosed |
| US-20110201801-A1 | SACCHARIDE STRUCTURES AND METHODS OF MAKING AND USING SUCH STRUCTURES | MOMENTA PHARAMACEUTICALS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201801-A1 | SACCHARIDE STRUCTURES AND METHODS OF MAKING AND USING SUCH STRUCTURES | FUT6, FUT5, SI | TNF 1608/4885MAPK1 4223/4885GJB2 4039/4885 |
| US-20140200339-A1 | SACCHARIDE STRUCTURES AND METHODS OF MAKING AND USING SUCH STRUCTURES | FUT6, FUT5, SI | TNF 1608/4885MAPK1 4223/4885GJB2 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.